Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Natamycin is a tetraene polyene antifungal drug derived from Streptomyces natalensis. It is primarily used as an ophthalmic suspension to treat fungal infections of the eye, including blepharitis, conjunctivitis, and keratitis caused by susceptible fungi such as Candida, Aspergillus, Fusarium, Acremonium (Cephalosporium), and Penicillium. Natamycin acts by binding specifically to ergosterol in the fungal cell membrane. This binding impairs membrane integrity and inhibits essential cellular processes like amino acid and glucose transport without directly causing membrane permeabilization—a mechanism distinct from other polyene antifungals. The result is fungicidal activity that halts fungal growth[2][4][5][7]. Systemic absorption after topical administration is negligible.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on natamycin.